Announcements Trials
Browse Landscape

Phase

Phase 1 18Phase 2 13Phase NA 4Phase 3 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 700Breast Neoplasms 630Neoplasms 583Leukemia, Myeloid, Acute 481Colorectal Neoplasms 457Multiple Myeloma 444Melanoma 426Prostatic Neoplasms 383Neoplasm Metastasis 374Pancreatic Neoplasms 364Recurrence 350Lymphoma 340Ovarian Neoplasms 325Lung Neoplasms 298Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 276Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 220Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Lymphoma, Mantle-Cell 167Triple Negative Breast Neoplasms 166

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Glioma, Subependymal × Clear all
NCT00010049 2018-06-27

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
105 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00002752 2014-07-16

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

Duke University

Phase 1/2 Completed
CNSSarcoma

Familial ependymoma, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neoplasm Metastasis, Oligodendroglioma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡